Alinix® Tablet: Each film-coated tablet contains Nitazoxanide INN 500 mg.
Alinix® Powder for Suspension: When reconstituted, each 5 ml suspension contains Nitazoxanide INN 100 mg.

Nitazoxanide is a synthetic antiprotozoal agent for oral administration. Both Nitazoxanide and its metabolite, tizoxanide, may exhibit antiprotozoal activity through various pathways. The primary mechanism is interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is crucial for anaerobic energy metabolism.

Diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Amebiasis and Trichomoniasis.
Helminth infections.

Follow the prescribing physician’s instructions for dosage and administration.

Nitazoxanide is contraindicated in patients with hypersensitivity to Nitazoxanide. It should be used with caution in patients with:
Biliary tract disease.
Hepatic disease.
Renal disease, renal failure, or renal impairment.
Combined renal and hepatic disease.

General: Use Nitazoxanide cautiously in patients with hepatic or biliary disease, renal disease, or combined renal and hepatic disease.
Information for Patients: Alinix® Tablets and Alinix® Oral Suspension should be taken with food.
Direction for Reconstitution of Suspension
Refer to the instructions provided on the carton for proper reconstitution.

Nitazoxanide is highly bound to plasma proteins (>99.9%). Caution should be exercised when administering it with other drugs that are highly plasma protein-bound (e.g., warfarin).

Pregnancy Category B: Animal studies have shown no evidence of impaired fertility or harm to the fetus due to Nitazoxanide. However, there are no adequate and well-controlled studies in pregnant women.

It is unknown whether Nitazoxanide is excreted in breast milk. Caution should be exercised when administering it to nursing women.

The most common adverse reactions reported include:
Abdominal pain (6.6%).
Diarrhea (4.2%).
Headache (3.1%).
Nausea (3.0%).

Store tablets, unsuspended powder, and reconstituted oral suspension at a temperature below 30°C.
Medicine: Keep out of reach of children.
